EichorEICHOR
Study identifier: NCT07335562 Synced from ClinicalTrials.gov · August 06, 2026
● Study status: Not Yet Recruiting

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Condition: Systemic Sclerosis  ·  Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

PhasePhase 3
Planned participants92
Who can joinAll sexes, 16 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis

This description comes directly from the study's public registry record.

Talk to the study team

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com  ·  855-907-3286  ·  Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Always discuss trial participation with your own doctor first.

Locations (56)

Local Institution - 0035Scottsdale, Arizona, United States
University of Colorado Anschutz Medical CampusAurora, Colorado, United States
Local Institution - 0001Denver, Colorado, United States
Local Institution - 0069Miami, Florida, United States
Emory University School of MedicineAtlanta, Georgia, United States
Local Institution - 0139Chicago, Illinois, United States
Local Institution - 0084Worcester, Massachusetts, United States
Local Institution - 0034Ann Arbor, Michigan, United States
Local Institution - 0037Rochester, Minnesota, United States
Local Institution - 0082Summit, New Jersey, United States
Cleveland ClinicCleveland, Ohio, United States
Local Institution - 0142Philadelphia, Pennsylvania, United States

+ 44 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →